PDCD1 and head and neck squamous cell carcinoma: Notably, it has been reported that the application of immunotherapy significantly improves the overall survival and quality of life of patients with HNSCC, especially in patients positive for HPV, PD-L1, or PD-1 (Cramer et al., 2019b; Galvis et al., 2020).